Aldeyra Therapeutics, Inc. (ALDX) announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the signs and symptoms of dry eye disease.With the FDA accepting the resubmitted NDA for review, a decision from the regulatory body is expected on April 2, 2025.Simultaneously, Aldeyra announced that it has expanded its existing option agreement with AbbVie (ABBV) .Shares of Aldeyra were up 11.6% on Nov. 18 fol ...